Published in Chem Biol on September 12, 2013
Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. Cell Chem Biol (2016) 0.92
The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nat Commun (2016) 0.81
An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein. Cancers (Basel) (2014) 0.79
An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. Antiviral Res (2016) 0.78
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget (2017) 0.78
Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity. Oncotarget (2016) 0.77
A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget (2016) 0.76
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Rethinking screening for breast cancer and prostate cancer. JAMA (2009) 7.83
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2010) 4.76
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther (1998) 3.66
Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol (2004) 3.58
The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem (1997) 3.16
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci (2007) 1.96
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol (2008) 1.88
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol (2005) 1.67
Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta (2011) 1.56
Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer (2010) 1.51
A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene (2007) 1.48
The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A (2009) 1.48
Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo. Cancer Res (2009) 1.47
Hsp90, an unlikely ally in the war on cancer. FEBS J (2013) 1.33
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27
An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS One (2011) 1.27
Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res (2009) 1.26
Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One (2011) 1.25
Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med (2007) 1.22
Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol (2009) 1.22
Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol (2010) 1.18
Monte-Carlo-based model for the extraction of intrinsic fluorescence from turbid media. J Biomed Opt (2008) 1.15
Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets (2003) 1.11
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res (2012) 1.09
Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol (2010) 1.09
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer (2010) 1.00
Understanding of the Hsp90 molecular chaperone reaches new heights. Nat Struct Mol Biol (2010) 0.94
Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release (2009) 0.92
The expanding proteome of the molecular chaperone HSP90. Cell Cycle (2012) 0.92
The complex dance of the molecular chaperone Hsp90. Trends Biochem Sci (2009) 0.88
Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging (2005) 0.87
A highly selective Hsp90 affinity chromatography resin with a cleavable linker. Bioorg Med Chem (2012) 0.86
Experimental validation of an inverse fluorescence Monte Carlo model to extract concentrations of metabolically relevant fluorophores from turbid phantoms and a murine tumor model. J Biomed Opt (2012) 0.86
The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimer. PLoS One (2011) 0.79
Utility of 18FDG-PET/CT in breast cancer diagnostics--a systematic review. Dan Med Bull (2011) 0.77
Phosphoproteome analysis in yeast. Methods Enzymol (2003) 0.76
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol (2004) 3.58
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A (2002) 3.54
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J (2003) 3.37
Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3.25
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J (2003) 2.78
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst (2012) 2.47
A conserved family of enzymes that phosphorylate inositol hexakisphosphate. Science (2007) 2.43
C-terminal repeat domain kinase I phosphorylates Ser2 and Ser5 of RNA polymerase II C-terminal domain repeats. J Biol Chem (2004) 2.42
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol (2005) 2.28
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med (2006) 2.10
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res (2007) 2.06
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci (2007) 1.96
Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell (2011) 1.94
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene (2004) 1.89
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res (2007) 1.88
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res (2007) 1.83
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol (2008) 1.78
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc (2006) 1.75
Use of tablet personal computers for sensitive patient-reported information. J Support Oncol (2009) 1.73
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther (2004) 1.72
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc (2005) 1.71
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol (2005) 1.67
Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med Care (2010) 1.67
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle (2009) 1.67
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res (2008) 1.65
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res (2007) 1.64
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Clostridium taeniosporum spore ribbon-like appendage structure, composition and genes. Mol Microbiol (2007) 1.58
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry (2009) 1.58
Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer (2011) 1.58
Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell (2008) 1.57
Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta (2011) 1.56
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A (2006) 1.55
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood (2003) 1.54
Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol (2002) 1.54
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res (2006) 1.53
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J (2003) 1.50
Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. Cell Cycle (2008) 1.48
Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release (2006) 1.48
Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res (2004) 1.45
Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem (2006) 1.44
IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab (2002) 1.43
Performance metrics of an optical spectral imaging system for intra-operative assessment of breast tumor margins. Opt Express (2010) 1.43
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol (2006) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Efficient detection of RNA-protein interactions using tethered RNAs. Nucleic Acids Res (2011) 1.39
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc (2006) 1.36
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res (2003) 1.35
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. J Nucl Med (2005) 1.35
Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell (2012) 1.35
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. J Nucl Med (2005) 1.34
Brain and central haemodynamics and oxygenation during maximal exercise in humans. J Physiol (2004) 1.34
The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des (2013) 1.33
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Rapid noninvasive optical imaging of tissue composition in breast tumor margins. Am J Surg (2009) 1.33
Hsp90, an unlikely ally in the war on cancer. FEBS J (2013) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood (2003) 1.32
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
A role for PP1 in the Cdc2/Cyclin B-mediated positive feedback activation of Cdc25. Mol Biol Cell (2006) 1.31
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res (2008) 1.30